Trial Profile
Pharmacokinetics, pharmacodynamics, and tolerability of indacaterol/mometasone (150/80 microg/day and 150/320 microg/day) in Japanese and Caucasian volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Oct 2015
Price :
$35
*
At a glance
- Drugs Indacaterol/mometasone (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 25 Oct 2013 New trial record
- 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.